📈 Stocks
📈 Bullish
🌍 United States
Invesco PJP Outperforms iShares IYH With 43% Annual Return in Healthcare Sector
Investors weighing healthcare exposure should consider PJP's aggressive, high-performing pharmaceutical focus against IYH's broader, lower-cost diversification strategy.
Impact
10/10
💡 Key Takeaways
- PJP delivered a 43.1% one-year return, significantly outpacing IYH's 27.4% gain.
- PJP maintains a lower 5-year maximum drawdown of 17.5% compared to 17.9% for IYH.
- IYH provides a more cost-effective entry with a 0.37% expense ratio versus 0.57% for PJP.
- PJP's portfolio is more aggressive, with 40% allocation in small-cap stocks compared to 6% for IYH.
📋 Executive Summary
The Invesco Pharmaceuticals ETF (PJP) has consistently outperformed the iShares U.S. Healthcare ETF (IYH) in recent years, delivering a 43.1% one-year return compared to 27.4% for its rival. While IYH offers broader diversification and a lower expense ratio, PJP's concentrated focus on 27 pharmaceutical firms has resulted in superior long-term growth and lower maximum drawdowns for investors.
📊 Sentiment Analysis
Sentiment
📈 Bullish
Impact Score
10/10
Region
🌍 United States
Asset Class
📈 Stocks
❓ Frequently Asked Questions
PJP is preferred for investors seeking higher growth and consistent outperformance, while IYH is better suited for those prioritizing lower fees and broader sector diversification.
📰 Source
📅 Originally published:
⚠️ Disclaimer: This content is for training purposes only and should not be considered financial advice. Always conduct your own research before making investment decisions.